Form SC 13G C4 Therapeutics, Inc. Filed by: BlackRock, Inc.
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of DirectorsGlobeNewswire
- C4 Therapeutics, Inc. (NASDAQ: CCCC) is now covered by analysts at Stephens. They set an "equal weight" rating and a $4.00 price target on the stock.MarketBeat
- C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical TrialGlobeNewswire
CCCC
Earnings
- 5/8/24 - In-Line
CCCC
Sec Filings
- 11/21/24 - Form 4
- 11/21/24 - Form 3
- 11/20/24 - Form 8-K
- CCCC's page on the SEC website